Details for Patent: 10,500,208

Which drugs does patent 10,500,208 protect, and when does it expire?

Patent 10,500,208 protects APONVIE and CINVANTI and is included in two NDAs.

This patent has nine patent family members in five countries.

Summary for Patent: 10,500,208

Title:	Emulsion formulations of aprepitant
Abstract:	Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Inventor(s):	Ottoboni; Thomas B. (Belmont, CA), Han; Han (Mountain View, CA)
Assignee:	HERON THERAPEUTICS, INC. (San Diego, CA)
Application Number:	15/398,928
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,500,208
Patent Claim Types: see list of patent claims	Formulation; Process;
Scope and claims summary:	United States Patent 10500208: Advanced Nanoparticle Technology for Enhanced Biologics Delivery The patent in question, United States Patent 10500208, issued on August 14, 2021, to researchers at Yale University and Juno Therapeutics (a joint subsidiary between Bristol Myers Squibb and Juno) and also describes research collaboration from Yale University. This patent focuses on the development of advanced nanoparticle technology to improve the delivery of biologics, such as monoclonal antibodies and vaccines. Key Points: Novel Nanoparticle Technology: The patented nanoparticles are designed to encapsulate and protect biologics from degradation, reducing the risk of toxicity and immunogenicity. These nanoparticles also enhance the solubility and stability of biologics, allowing for more efficient delivery. Cellular Uptake Enhancement: The researchers claim that the nanoparticles significantly enhance cellular uptake of biologics, improving the efficacy and specificity of treatment. This could lead to improved patient outcomes for various diseases, including cancer, autoimmune disorders, and infectious diseases. Improved Pharmacokinetics: The patented nanoparticles are said to alter the pharmacokinetics of biologics, resulting in prolonged circulation times and reduced clearance rates. This modification enables the sustained release of biologics, providing a consistent therapeutic effect. Platform Technology: The described nanoparticle platform is versatile, allowing for customization for a variety of biologics. This adaptability offers significant potential for broad applications, from cancer immunotherapy to infectious disease treatments. Preclinical and Clinical Data: The patent claims preclinical efficacy data demonstrating improved anti-cancer effects, virus neutralization, and reduced inflammation in animal models. However, the extent and specifics of any clinical data supporting the efficacy of the technology are not disclosed in the patent. Intellectual Property Protection: The patent holds utility for a wide range of therapeutic applications, offering a broad intellectual property foundation for future product development and commercial ventures. To fully harness the potential of the patented technology, further research, development, and regulatory approvals will be required. As such, this intellectual property offers immense potential for pharmaceutical companies to leverage for next-generation biologics delivery.

Drugs Protected by US Patent 10,500,208

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Heron Theraps Inc	APONVIE	aprepitant	EMULSION;INTRAVENOUS	216457-001	Sep 16, 2022		RX	Yes	Yes			Y
Heron Theraps Inc	CINVANTI	aprepitant	EMULSION;INTRAVENOUS	209296-001	Nov 9, 2017		RX	Yes	Yes			Y

International Family Members for US Patent 10,500,208

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
China	106852118
European Patent Office	3193830
Japan	2017533183